Making Merrimack

Merrimack Pharmaceuticals Inc. made its highly anticipated entrance into the biotech IPO queue late last week when the oncology play filed to raise up to $172.5 million.

The company already had raised $191.3 million in equity prior to a $77 million series G round that closed in April, and another $98.1 million from partners...